News Channels

05 Sep 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
05 Sep 2018 Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke
05 Sep 2018 Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
05 Sep 2018 Lysogene Announces FDA approval of IND Application to Initiate Phase 2-3 Clinical Trial in MPS IIIA
05 Sep 2018 Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
05 Sep 2018 ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
05 Sep 2018 Aduro Biotech Presents Preclinical Data for BION-1301, a First-in-Class Antibody Targeting Human APRIL, at the 2018 European Congress of Immunology
05 Sep 2018 Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
04 Sep 2018 Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma
04 Sep 2018 Abivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients
04 Sep 2018 Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
04 Sep 2018 Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
04 Sep 2018 Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
04 Sep 2018 Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies
04 Sep 2018 European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
04 Sep 2018 Ossianix and Novo Nordisk Sign Research and Option Agreement on Blood Brain Barrier Delivery Technology for Proteins in Diabetes and Other Metabolic Diseases
04 Sep 2018 SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
04 Sep 2018 Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
04 Sep 2018 Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
04 Sep 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up